Newer glucose-lowering agents, including glucagon-like peptide (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors have been assessed in participants with T2DM and NAFLD, because of their multiple pleiotropic effects [9,10]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.